328 Stock Overview A clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
MeiraGTx Holdings plc Competitors Price History & Performance
Summary of share price highs, lows and changes for MeiraGTx Holdings Historical stock prices Current Share Price US$5.80 52 Week High US$6.70 52 Week Low US$3.40 Beta 1.25 1 Month Change 4.50% 3 Month Change 62.92% 1 Year Change -3.33% 3 Year Change -71.00% 5 Year Change -67.96% Change since IPO -63.26%
Recent News & Updates
MeiraGTx Holdings plc Grants FDA Regenerative Medicine Advanced Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia Dec 10
Third quarter 2024 earnings released: US$0.55 loss per share (vs US$0.74 loss in 3Q 2023) Nov 14
MeiraGTx Holdings plc Announces Positive Data from Randomized, Sham-Controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease Oct 15
Second quarter 2024 earnings released: US$0.76 loss per share (vs US$0.53 loss in 2Q 2023) Aug 13 MeiraGTx Holdings plc has completed a Follow-on Equity Offering in the amount of $50 million.
First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023) May 09 See more updates
MeiraGTx Holdings plc Grants FDA Regenerative Medicine Advanced Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia Dec 10
Third quarter 2024 earnings released: US$0.55 loss per share (vs US$0.74 loss in 3Q 2023) Nov 14
MeiraGTx Holdings plc Announces Positive Data from Randomized, Sham-Controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease Oct 15
Second quarter 2024 earnings released: US$0.76 loss per share (vs US$0.53 loss in 2Q 2023) Aug 13 MeiraGTx Holdings plc has completed a Follow-on Equity Offering in the amount of $50 million.
First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023) May 09
MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024 Apr 27
MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board Apr 17
Full year 2023 earnings released: US$1.49 loss per share (vs US$2.87 loss in FY 2022) Mar 15
Forecast to breakeven in 2025 Dec 23 MeiraGTx Holdings plc has filed a Follow-on Equity Offering in the amount of $100 million. Dec 21
Third quarter 2023 earnings released: US$0.74 loss per share (vs US$0.83 loss in 3Q 2022) Nov 15
MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V. Oct 31
New major risk - Share price stability Oct 26
MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress Oct 26
New major risk - Financial position Aug 11
Second quarter 2023 earnings released: US$0.53 loss per share (vs US$0.76 loss in 2Q 2022) Aug 11
MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia Jun 29
MeiraGTx Holdings plc to Present 12-Month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study Jun 23
First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.70 loss in 1Q 2022) May 12 MeiraGTx Holdings plc announced that it expects to receive $61.525 million in funding from Perceptive Advisors LLC, 683 Capital Management, LLC, Prosight Management, LP, Adage Capital Management, L.P. May 05
Full year 2022 earnings released: US$2.87 loss per share (vs US$1.80 loss in FY 2021) Mar 15
MeiraGTx Holdings plc cAnnounces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia Dec 14
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.59 loss in 3Q 2021) Nov 11 MeiraGTx Holdings plc announced that it has received $24.999994 million in funding from Johnson & Johnson Innovation - JJDC, Inc. Nov 11
MeiraGTx Holdings plc Announces the Primary Results from the Phase 1/2 Study Evaluating the Investigational Gene Therapy Botaretigene Sparoparvovec in Patients with the Inherited Retinal Disease X-Linked Retinitis Pigmentosa (XLRP) Associated with the Retinitis Pigmentosa GTPase Regulator (RPGR) Gene Oct 04
Second quarter 2022 earnings released: US$0.76 loss per share (vs US$0.46 loss in 2Q 2021) Aug 12 MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC Aug 05
MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC Aug 04
MeiraGTx Holdings plc Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients Treated with Botaretigene Sparoparvovec (AAV-RPGR) Compared to Untreated Randomized Control
First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.54 loss in 1Q 2021) May 13
MeiraGTx Holdings plc Presents Clinical Data on Botaretigene Sparoparvovec for Treatment of X-Linked Retinitis Pigmentosa at Association for Research in Vision and Ophthalmology 2022 Annual Meeting May 05
MeiraGTx Holdings plc, Annual General Meeting, Jun 07, 2022 May 03
MeiraGTx Appoints Debra Yu to Board of Directors Apr 28
Insufficient new directors Apr 27
Insufficient new directors Apr 01
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 11
Insufficient new directors Mar 02
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia Dec 08
Third quarter 2021 earnings released: US$0.59 loss per share (vs US$0.17 loss in 3Q 2020) Nov 12
Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.69 loss in 2Q 2020) Aug 12
Forecast to breakeven in 2025 May 18
First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.43 loss in 1Q 2020) May 13
Full year 2020 earnings released: US$1.54 loss per share (vs US$1.65 loss in FY 2019) Mar 13
Revenue misses expectations Mar 13
MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia Jan 28
MeiraGTx Holdings plc to Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia Dec 19
New 90-day low: €10.00 Dec 11
Meiragtx Holdings plc and Chardan Capital Markets, LLC Announce Termination of a Material Definitive Agreement Nov 19
MeiraGTx Holdings plc Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment Nov 14
New 90-day high: €12.30 Nov 07
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: US$0.17 loss per share Nov 07 MeiraGTx Holdings plc Reports Clinical Development
MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP) Oct 04
MeiraGTx Holdings plc Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa Sep 24
MeiraGTx Holdings plc (NasdaqGS:MGTX) acquired Emrys Bio Inc. for $7.7 million. Aug 21 Shareholder Returns 328 DE Biotechs DE Market 7D 1.8% -3.5% -2.0% 1Y -3.3% -14.7% 6.9%
See full shareholder returns
Return vs Market: 328 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 328's price volatile compared to industry and market? 328 volatility 328 Average Weekly Movement 10.4% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 328's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 328's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 2015 389 Alexandria Forbes meiragtx.com
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson’s program that has completed a Phase II trial.
Show more MeiraGTx Holdings plc Fundamentals Summary How do MeiraGTx Holdings's earnings and revenue compare to its market cap? 328 fundamental statistics Market cap €461.85m Earnings (TTM ) -€84.73m Revenue (TTM ) €13.38m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 328 income statement (TTM ) Revenue US$13.93m Cost of Revenue US$11.99m Gross Profit US$1.94m Other Expenses US$90.12m Earnings -US$88.18m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.13 Gross Margin 13.96% Net Profit Margin -633.05% Debt/Equity Ratio 76.2%
How did 328 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 23:58 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources MeiraGTx Holdings plc is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Huidong Wang Barclays Alec Stranahan BofA Global Research Gbolahan Amusa Benz Chardan Capital Markets, LLC
Show 7 more analysts 
